Perioperative infusion of low- dose of vasopressin for prevention and management of vasodilatory vasoplegic syndrome in patients undergoing coronary artery bypass grafting-A double-blind randomized study

Georgios Papadopoulos, Eleni Sintou, Stavros Siminelakis, Efstratios Koletsis, Nikolaos G Baikoussis, Efstratios Apostolakis, Georgios Papadopoulos, Eleni Sintou, Stavros Siminelakis, Efstratios Koletsis, Nikolaos G Baikoussis, Efstratios Apostolakis

Abstract

Preoperative medication by inhibitors of angiotensin-converting enzyme (ACE) in coronary artery patients predisposes to vasoplegic shock early after coronary artery bypass grafting. Although in the majority of the cases this shock is mild, in some of them it appears as a situation, "intractable" to high-catecholamine dose medication. In this study we examined the possible role of prophylactic infusion of low-dose vasopressin, during and for the four hours post-bypass after cardiopulmonary bypass, in an effort to prevent this syndrome. In addition, we studied the influence of infused vasopressin on the hemodynamics of the patients, as well as on the postoperative urine-output and blood-loss. In our study 50 patients undergoing coronary artery bypass grafting were included in a blind-randomized basis. Two main criteria were used for the eligibility of patients for coronary artery bypass grafting: ejection fraction between 30-40%, and patients receiving ACE inhibitors, at least for four weeks preoperatively. The patients were randomly divided in two groups, the group A who were infused with 0.03 IU/min vasopressin and the group B who were infused with normal saline intraoperativelly and for the 4 postoperative hours. Measurements of mean artery pressure (MAP), central venous pressure (CVP), systemic vascular resistance (SVR), ejection fracture (EF), heart rate (HR), mean pulmonary artery pressure (MPAP), cardiac index (CI) and pulmonary vascular resistance (PVR) were performed before, during, and after the operation. The requirements of catecholamine support, the urine-output, the blood-loss, and the requirements in blood, plasma and platelets for the first 24 hours were included in the data collected. The incidence of vasodilatory shock was significantly lower (8% vs 20%) in group A and B respectively (p = 0,042). Generally, the mortality was 12%, exclusively deriving from group B. Postoperatively, significant higher values of MAP, CVP, SVR and EF were recorded in the patients of group A, compared to those of group B. In group A norepinephrine was necessary in fewer patients (p = 0.002) and with a lower mean dose (p = 0.0001), additive infusion of epinephrine was needed in fewer patients (p = 0.001), while both were infused for a significant shorter infusion-period (p = 0.0001). Vasopressin administration (for group A) was associated with a higher 24 hour diuresis) (0.0001).In conclusion, low-dose of infused vasopressin during cardiopulmonary bypass and for the next 4 hours is beneficial for its postoperative hemodynamic profile, reduces the doses of requirements of catecholamines and contributes to prevention of the postcardiotomy vasoplegic shock in the patient with low ejection fraction who is receiving ACE preoperatively.

Figures

Figure 1
Figure 1
Mean Pulmonary Pressure during time-points T1 - T5. Distribution of values for mean pulmonary pressure (MPAP) during time-points T1 - T5 for group I (vasopressin, in blue boxplots) and group II (placebo, in green boxplots). (median = black line, boxplot = 50% of data set, lines on both sides of the boxplot = dispersion for 99% of values, * = numbers outside of distribution range for 99% of values).
Figure 2
Figure 2
Cardiac Index during time-points T1 - T5. Distribution of values for cardiac index (CI) during time-points T1 - T5 for group I (vasopressin, in blue boxplots) and group II (placebo, in green boxplots). (median = black line, boxplot = 50% of data set, lines on both sides of the boxplot = dispersion for 99% of values, * = numbers outside of distribution range for 99% of values).
Figure 3
Figure 3
Mean arterial pressure values during time-points T1 - T5. Distribution of mean arterial pressure (MAP) values during time-points T1 - T5 for group I (vasopressin, in blue boxplots) and group II (placebo, in green boxplots). (median = black line, boxplot = 50% of data set, lines on both sides of the boxplot = dispersion for 99% of values, * = numbers outside of distribution range for 99% of values).
Figure 4
Figure 4
Central Venous Pressure during time- points T1 - T5. Distribution of values for central venous pressure (CVP) during time- points T1 - T5 for group I (vasopressin, in blue boxplots) and group II (placebo, in green boxplots). (median = black line, boxplot = 50% of data set, lines on both sides of the boxplot = dispersion for 99% of values, * = numbers outside of distribution range for 99% of values).
Figure 5
Figure 5
Systemic Vascular Resistance during time-points T1 - T5. Distribution of values for peripheral resistance (SVR) during time-points T1 - T5 for group I (vasopressin, in blue boxplots) and group II (placebo, in green boxplots). (median = black line, boxplot = 50% of data set, lines on both sides of the boxplot = dispersion for 99% of values, * = numbers outside of distribution range for 99% of values).
Figure 6
Figure 6
Left ventricular Ejection Fraction during time-points T1 - T5. Distribution of values for left ventricular ejection fraction (E.F.) during time-points T1 - T5 for group I (vasopressin, in blue boxplots) and group II (placebo, in green boxplots). (median = black line, boxplot = 50% of data set, lines on both sides of the boxplot = dispersion for 99% of values, * = numbers outside of distribution range for 99% of values).

References

    1. Carrel T, Englberger L, Mohacsi P, Neidhart P, Schmidli J. Low systemic vascular resistance after cardiopulmonary bypass: incidence, etiology, and clinical importance. J Card Surg. 2000;15:347–353. doi: 10.1111/j.1540-8191.2000.tb00470.x.
    1. Sun X, Zhang L, Hill PC, Lowery R, Lee AT, Molyneaux RE, Corso PJ, Boyce SW. Is incidence of postoperative vasoplegic syndrome different between off-pump and on-pump coronary artery bypass grafting surgery? Eur J Cardiothorac Surg. 2008;34:820–825. doi: 10.1016/j.ejcts.2008.07.012.
    1. Noto A, Lentini S, Versaci A, Giardina M, Risitano DC, Messina R, David A. A retrospective analysis of terlipressin in bolus for the management of refractory vasoplegic hypotension after cardiac surgery. Interact CardioVascular and Thoracic Surgery. 2009;9:588–92. doi: 10.1510/icvts.2009.209890.
    1. Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology. 2002;97:215–52. doi: 10.1097/00000542-200207000-00030.
    1. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med. 2001;345:588–595. doi: 10.1056/NEJMra002709.
    1. Wenzel V, Krismer AC, Arntz HR, Sitter H, Stadlbauer KH, Lindner KH. A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med. 2004;350:105–113. doi: 10.1056/NEJMoa025431.
    1. Gomes WJ, Carvalho AC, Palma JH, Goncalves I Jr, Buffolo E. Vasoplegic syndrome: a new dilemma. J Thorac Cardiovasc Surg. 1994;107:942–3.
    1. Gomes WJ, Carvalho AC, Palma JH, Teles CA, Branco JN, Silas MG, Buffolo E. Vasoplegic syndrome after open heart surgery. J Cardiovasc Surg (Torino) 1998;39:619–23.
    1. Levin RL, Degrange MA, Bruno GF, Del Mazo CD, Taborda DJ, Griotti JJ, Boullon FJ. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg. 2004;77:496–9. doi: 10.1016/S0003-4975(03)01510-8.
    1. Shanmugam G. Vasoplegic syndrome-the role of methylene blue. Eur J Cardio-thoracic Surg. 2005;28:705–10. doi: 10.1016/j.ejcts.2005.07.011.
    1. Argenziano M, Chen J, Choundhri A, Cullinane S, Garfein E, Weinberg AD, Smith CR Jr, Rose EA, Landry DW, Oz MC. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg. 1998;116:973–80. doi: 10.1016/S0022-5223(98)70049-2.
    1. Luckner G, Duenser M, Jochberger S, Mayr VD, Wenzel V, Ulmer H, Schmid S, Knotzer H, Pajk W, Hasibeder W, Mayr AJ, Friesenecker B. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med. 2005;33:2659–2666. doi: 10.1097/01.CCM.0000186749.34028.40.
    1. Duenser MW, Wenzel V, Mayr AJ, Hasibeder WR. Management of vasodilatory shock: Defining the role of arginine vasopressin. Drugs. 2003;63:237–256. doi: 10.2165/00003495-200363030-00001.
    1. Duenser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR. Arginine vasopressin in advanced vasodilatory shock: A prospective, randomized, controlled study. Circulation. 2003;107:2313–2319. doi: 10.1161/.
    1. Morales D, Garrido M, Madigan J, Helman D, Faber J, Williams M, Landry D, Oz M. A double-blind randomized trial: Prophylactic Vasopressin Reduces Hypotension After Cardiopulmonary Bypass. Ann Thorac Surg. 2003;75:926–30. doi: 10.1016/S0003-4975(02)04408-9.
    1. Morales D, Gregg D, Helman D, Williams MR, Naka Y, Landry DW, Oz MC. Arginine vasopressin in the treatment of fifty patients with postcardiotomy vasodilatory shock. Ann Thorac Surg. 2000;69:102–6. doi: 10.1016/S0003-4975(99)01197-2.
    1. Raja S, Dreyfus G. Vasoplegic syndrome after Off-pump coronary artery bypass surgery. Tex Heart Inst J. 2004;31:421–24.
    1. Mekontso-Dessap A, Houel R, Soustelle C, Kirsch M, Thebert D, Loisance DY. Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. Ann Thorac Surg. 2001;71:1428–32. doi: 10.1016/S0003-4975(01)02486-9.
    1. Tuman KJ, McCarthy RJ, O'Connor CJ, Holm WE, Ivankovich AD. Angiotensin-converting enzyme inhibitors increase vasoconstrictor requirements after cardiopulmonary bypass. Anesth Analg. 1995;80:473–9. doi: 10.1097/00000539-199503000-00007.
    1. Mets B, Michler RE, Delphin ED, Oz MC, Landry DW. Refractory vasodilation after cardiopulmonary bypass for heart transplantation in recipients on combined amiodarone and angiotensin-converting enzyme inhibitor therapy: a role for vasopressin administration. J Cardiothorac Vasc Anesth. 1998;12:326–9. doi: 10.1016/S1053-0770(98)90017-9.
    1. Argengiano M, Choudhri A, Oz M, Rose E, Smith C, Landry D. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation. 1997;96:286–290.
    1. Carrel T, Englberger L, Mohacsi P, Neidhart P, Schmidli J. Low systemic vascular resistance after cardiopulmonary bypass: incidence, etiology, and clinical importance. J Card Surg. 2000;15:347–53. doi: 10.1111/j.1540-8191.2000.tb00470.x.
    1. Patel B, Chittock D, Russell J, Walley K. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002;96:576–82. doi: 10.1097/00000542-200203000-00011.
    1. Suojaranta-Ylinen R, Vento R, Patila T, Kukkonen S. Vasopressin, when added to norepinephrine, was not associated with increased predicted mortality after cardiac surgery. Scand J Surg. 2007;96:314–18.
    1. Morales DL, Landry DW, Oz MC. Therapy for vasodilatory shock: Arginine vasopressin. Semin Anesth Periop Med. 2000;19:98–107. doi: 10.1053/sa.2000.6789.
    1. Masetti P, Murphy SF, Kouchoukos NT. Vasopressin therapy for vasoplegic syndrome following cardiopulmonary bypass. J Card Surg. 2002;17:485–9. doi: 10.1046/j.1540-8191.2002.01002.x.
    1. Malay MB, Ashton RC Jr, Landry DW, Townsend RN. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma. 1999;47:699–705. doi: 10.1097/00005373-199910000-00014.
    1. Albright T, Zimmerman M, Selzman C. Vasopressin in the cardiac surgery intensive care unit. Am J Crit Care. 2002;11:326–332.
    1. Mutlu G, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med. 2004;30:1276–91.
    1. Torqersen C, Duenser M, Wenzel V, Jochberger S, Mayr V, Schmittinger CA, Lorenz I, Schmid S, Westphal M, Grander W, Luckner G. Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. Intensive Care Med. 2009;36:57–65. doi: 10.1007/s00134-009-1630-1.
    1. Argenziano M, Chen JM, Cullinane S, Choudhri AF, Rose EA, Smith CR, Edwards NM, Landry DW, Oz MC. Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. J Heart Lung Transplant. 1999;18:814–817. doi: 10.1016/S1053-2498(99)00038-8.
    1. Tayama E, Ueda T, Shojima T, Akasu K, Oda T, Fukunaga S, Akashi H, Aoyagi S. Arginine vasopressin is an ideal drug after cardiac surgery for the management of low systemic vascular resistant hypotension concomitant with pulmonary hypertension. Interact CardioVasc Thorac Surg. 2007;6:715–719. doi: 10.1510/icvts.2007.159624.
    1. Leone M, Albanese J, Delmas A, Chaabane W, Garnier F, Martin C. Terlipressin in catecholamine-resistant septic shock patients. SHOCK. 2004;22:314–319. doi: 10.1097/.
    1. Novella S, Martínez C, Pagán R, Hernández R, García-Sacristán A, González-Pinto A, González-Santos J, Benedito S. Plasma levels and vascular effects of vasopressin in patients undergoing coronary artery bypass grafting. Eur J Cardiothorac Surg. 2007;32:69–76. doi: 10.1016/j.ejcts.2007.03.047.
    1. Delmas A, Leone M, Rousseau S, Albanese J, Martin C. Clinical review: Vasopressin and terlipressin in septic shock patients. Critical Care. 2005;9:212–222. doi: 10.1186/cc2945.
    1. Wenzel V, Lindner K. Employing vasopressin during cardiopulmonary resuscitation and vasodilatory shock as a lifesaving vasopressor. Cardiovascular Research. 2001;51:529–541. doi: 10.1016/S0008-6363(01)00262-0.
    1. Wenzel V, Lindner K, Prengel A, Maier C, Voelckel W, Lurie KG, Strohmenger HU. Vasopressin improves vital organ blood flow after prolonged cardiac arrest with postcounter-shock pulseless activity in pigs. Crit Care Med. 1999;27:486–92. doi: 10.1097/00003246-199903000-00022.
    1. Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: A case series. Intensive Care Med. 2001;27:1416–21. doi: 10.1007/s001340101014.
    1. Bragadottir G, Redfors B, Nygren A, Sellgren J, Ricksten SE. Low-dose vasopressin increases glomerular filtration rate, but impairs renal oxygenation in post-cardiac surgery patients. Acta Anesthesiol Scand. 2009;53:1052–59. doi: 10.1111/j.1399-6576.2009.02037.x.
    1. Duenser MW, Fries DR, Schobersberger W, Ulmer H, Wenzel V, Friesenecker B, Hasibeder WR, Mayr AJ. Does arginine vasopressin influence the coagulation system in advanced vasodilatory shock with severe multiorgan dysfunction syndrome? Anesth Analg. 2004;99:201–206. doi: 10.1213/01.ANE.0000118105.85933.8A.
    1. Treschan T, Peters J. The vasopressin system: Physiology and clinical strategies. Anesthesiology. 2006;105:599–612. doi: 10.1097/00000542-200609000-00026.
    1. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first twenty years. Haemophilia. 2000;6:60–7. doi: 10.1046/j.1365-2516.2000.00059.x.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅